Reanalysis of Clinical Trial Data Confirms LipiGesic® M has Robust Efficacy for Treatment of Migraine Headache and Associated Symptoms

Mar 05, 2013, 13:58 ET from PuraMed BioScience, Inc.

SCHOFIELD, Wis., March 5, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (PMBS: OTCBB) announces that the reanalysis of the clinical trial results of its homeopathic formulation, LipiGesic® M, found that the migraine medication has "robust efficacy." These results were featured in the February 2013 issue of Headache: The Journal of Head and Face Pain, the official journal of the American Headache Society®.

The article, Sublingual Feverfew/Ginger (LipiGesic M) Reanalysis of Data (attributed to Roger Cady, MD; Richard Lipton, MD; Daniel Serrano, PhD; and Rebecca Browning, BS) quoted Dr. Serrano, who provided the reanalysis as saying, "In conclusion, irrespective of design-type employed, the efficacy of sublingual feverfew/ginger (LipiGesic M) appears robust..."

The original double-blind, placebo-controlled clinical trial for LipiGesic M, completed in 2010 and published in the July 2011 issue of Headache: The Journal of Head and Face Pain, concluded that 64 percent of patients who used LipiGesic M found relief.

"This reanalysis not only confirms LipiGesic M is a highly effective, over-the-counter medication for the treatment of acute migraine pain," said Russell Mitchell, chairman and CEO of PuraMed BioScience. "It also shows that if our study had included a larger patient population, LipiGesic M would have demonstrated a stronger efficacy across all measurement points."

In a preceding article published in Drugs in 2012, Ryan Cady, Candace Shade, and Roger Cady, MD, describe LipiGesic M as an "excellent first-line therapy." The article "Advances in Drug Development for Acute Migraine" goes on to cite LipiGesic M's lower cost, its OTC availability, its unlikelihood to cause rebound headache, and its compatibility with other treatment options as advantages in acute migraine treatment.

"We have provided a safe, highly effective, OTC solution to migraine pain that performs as well as, if not better than prescription medications without the high cost, drowsiness, or the need for a doctor's visit," said Mitchell. "We are looking forward to the findings of the children's study that was recently concluded to compare results across all age groups."

LipiGesic® M is distributed nationally in Walgreens and CVS/pharmacy stores.

About PuraMed BioScience®, Inc.:
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products.

In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches as well as LipiGesic PM, which provides a remedy for insomnia and other sleep disorders.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
Product Website:
Corporate Website:

SOURCE PuraMed BioScience, Inc.